OneSource Specialty Pharma Ltd (ONESOURCE) — shareholding pattern, promoter holding, financials and share price
About OneSource Specialty Pharma Ltd (ONESOURCE)
OneSource Specialty Pharma Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as ONESOURCE and on the BSE under scrip code 544292. Its ISIN is INE013P01021.
Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio logical drug products in various injectable formats. It also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics [1]
Onesource Specialty Pharma Limited is a CDMO focused on biologics and injectables, offering end-to-end services for drug development and manufacturing.
The company's Q3FY26 performance was impacted by customer approval delays, but it maintains strong business fundamentals with an upward trending order book.
Listed peers in Pharmaceuticals: Astrazeneca Pharma India Ltd, ERIS Lifesciences Ltd, Caplin Point Laboratories Ltd, Natco Pharma Ltd, Cohance Lifesciences Ltd, Alembic Pharmaceuticals Ltd.
Valuation & Returns
10 Jul 2026At ₹1,632 a share on 10 Jul 2026, OneSource Specialty Pharma Ltd (ONESOURCE) was valued at a price-to-earnings ratio of -250.9x against an industry P/E of 36.41x and a price-to-book of 3.18x on a book value of ₹512.93 per share as of Mar 2025. Solomo computes return on equity of -1.25% and return on capital employed of 0.45% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- -250.9x
- Industry P/E
- 36.41x
- P/B
- 3.18x
- EPS (TTM)
- ₹-6.44
- Book value / share
- ₹512.93
- ROE
- -1.25%
- ROCE
- 0.45%
- ROA
- -0.98%
- Debt / equity
- 0.13x
- Dividend yield
- 0%
- EBITDA margin
- 21.76%
- 52-week range
- ₹1,075 – ₹2,082.1
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, OneSource Specialty Pharma Ltd (ONESOURCE) reported revenue of ₹1,422 crore, net profit of ₹-74 crore and earnings per share of ₹-6.44. That compares with revenue of ₹1,445 crore and net profit of ₹-18 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹428.22 crore and net profit ₹4.6 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 132 | 39 | 172 | 1,445 | 1,422 |
| Net profit (₹ cr) | -231 | -800 | -391 | -18 | -74 |
| EPS (₹) | - | - | - | -1.57 | -6.44 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 284.72% | 114.26% | 740.42% |
| Profit growth | - | - | 95.41% |
| Stock price CAGR | - | - | -16% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 30.48% of OneSource Specialty Pharma Ltd (ONESOURCE) (unchanged from the previous quarter), foreign institutional investors (FII) hold 19.19% and domestic institutional investors (DII) hold 23.38%. Promoters have pledged 37.2% of their holding. Market capitalisation was ₹18,710 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2024.
Largest disclosed public shareholders in Jun 2026: MOTILAL OSWAL MUTUAL FUND 7.06%, AUTHUM INVESTMENT AND INFRASTRUCTURE LIMITED 4.96%, ROUTE ONE OFFSHORE MASTER FUND L.P. 2.32%, ROUTE ONE FUND I, L.P. 2.07%, SBI LIFE INSURANCE CO. LTD 2.06%, AMANSA HOLDINGS PRIVATE LIMITED 1.86%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 30.48% | 37.2% | 19.19% | 23.38% | 69.52% |
| Mar 2026 | 30.48% | 38.4% | 17.5% | 20.61% | 69.52% |
| Dec 2025 | 29.93% | 18.5% | 19.24% | 18.81% | 70.07% |
| Sep 2025 | 29.77% | 26% | 19.39% | 18.49% | 70.23% |
| Jun 2025 | 29.79% | 25% | 18.69% | 18.1% | 70.21% |
| Mar 2025 | 34.25% | 20.1% | 18.54% | 18.04% | 65.75% |
| Dec 2024 | 37.77% | 9.6% | 17.44% | 12.56% | 62.23% |